| P/E (FY) | — | Sales (TTM) | $2.8M |
| Earnings (TTM) | -$398,429 | ROE | 14.96% |
| Net Margin | — | ROIC | −162.88% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $263.8M | Trading Days | 1187 |
| 52W High | 5.15 |
| 52W Low | 1.85 |
| % Off High | −33.01% |
| YTD | −7.75% | 1Y | 36.36% |
| 3Y | −58.98% | Since incept. (ann.) | −50.52% |
| Ann. Volatility (1Y) | 77.30% | Ann. Volatility (3Y) | 99.60% |
| Sharpe (1Y) | 0.79 | Sharpe (3Y) | 0.20 |
| Max Drawdown (1Y) | −30.11% | Max Drawdown (3Y) | −88.96% |
| Beta (3Y, vs SPY) | −0.79 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | $266.7M | — |
| ARTV | Artiva Biotherapeutics, Inc. | $260.3M | — |
| FATE | FATE THERAPEUTICS INC | $270.4M | — |
| EDIT | Editas Medicine, Inc. | $256.5M | — |
| AGEN | AGENUS INC | $274.8M | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $238.2M | — |
| IKT | Inhibikase Therapeutics, Inc. | $305.0M | — |
| NMRA | Neumora Therapeutics, Inc. | $307.6M | — |
| SRZN | Surrozen, Inc./DE | $225.2M | — |
| CHRS | Coherus Oncology, Inc. | $222.1M | 1.0 |
| TARA | Protara Therapeutics, Inc. |
| $214.7M |
| — |
| BCAB | BioAtla, Inc. | $207.7M | — |
